B+
Bull case
25%
Probability
Target price
$6.00
+29.9% vs current
NRXP
NRXCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$3.40
-26.4% vs current
B-
Bear case
30%
Probability
Target price
$1.50
-67.5% vs current
AI sentiment snapshot
Latest data as of 2026-05-16
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+23.7
Score
AI commentary
Sentiment remains cautious and monitoring-oriented. The deterministic prior improved versus the April baseline, but the evidence still looks like a filing-led setup rather than a fully confirmed post-earnings thesis. Importantly, the queue labeled this a T+3 earnings follow-up for May 13, 2026, while the company’s own May 14 press release said first-quarter 2026 results would be released on May 18, 2026; as of May 16, delayed analyst revisions and a clean market-reaction read were still unavailable. The 10-Q does support live regulatory and liquidity milestones, but without confirmed post-print sell-side digestion this should stay low-conviction. [#PR-2026-05-14] [#10-Q-2026-05-15]
RankAlpha Sentiment Codex - 2026-05-16
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-18catalystMay 18, 2026 earnings release and corporate update should resolve the timing mismatch in this follow-up runHigh impact
NRx said on May 14, 2026 that it plans to release first-quarter 2026 financial results before the market opens on May 18, 2026. As of May 16, 2026, that means this scheduled T+3 follow-up arrived before the company’s announced earnings release date, so delayed analyst reaction and a clean post-print market read are still unavailable. [#PR-2026-05-14]
2026-06-30eventNRX-100 NDA filing target in Q2 2026 is still live but remains a filing milestone, not an approvalHigh impact
The Q1 2026 10-Q says the NRX-100 NDA is expected to be filed during Q2 2026 and that FDA agreed in written Type C meeting minutes to review real-world evidence as part of the approval process. That is meaningful regulatory progress, but the upside depends first on filing completion and then on FDA review rather than on a de-risked approval outcome today. [#10-Q-2026-05-15]
2026-07-31eventKETAFREE ANDA review remains the clearest near-term regulatory swing factorHigh impact
The Q1 2026 10-Q says the KETAFREE ANDA was filed in September 2025, FDA discipline review letters identified no major deficiencies, the manufacturing site was inspected with VAI status, and management was told FDA was endeavoring to complete product review by Summer 2026. The same filing says commercial-scale manufacturing has started, but approval timing is still management-described rather than formally granted. [#10-Q-2026-05-15]
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-16 • Updated nightlySource: Internal modelMethodology